AA520 can reduce inflammation and pain associated with tumors that exhibit high expression of both PPARα and COX-2, such as advanced RCC (Chen et al., 2004; Abu Aboud et al., 2013), for which there are no effective therapies that prevent its progression. Here, PTGS2 is linked to renal cell carcinoma.